At Triangulum, our mission is to provide scientists in the Biopharma industry with world class pre-clinical pharmacology services.
Triangulum is founded with the vision of supporting scientists and innovators accelerate drug development, leveraging our portfolio of extensive industry experience in small molecule, biologics and RNA-based therapeutics. Our customer-centric approach and commitment enables you to bring modern medicines rapidly to the patients.
The company is headquartered, and has its operations in San Diego, California. Triangulum consists of a team of professionals with a collective experience of over 60 years. Together, we have authored over 100 publications, abstracts, scientific presentations, book chapters and patents. Several of the compounds our scientists have previously worked on are now in clinical phases of development.
Nonalcoholic Steatohepatitis (NASH) is a progressive form of Nonalcoholic Fatty Liver Disease (NAFLD) and has emerged to be a critical public health issue. It is anticipated that NASH will become the most common indication for liver transplantation in next ten years in the United States. NASH has strong association with diabetes, obesity and metabolic syndrome, and this disease is characterized by excessive triglyceride storage in the liver, insulin resistance and progress through stages of inflammation, fibrosis to cirrhosis and associated with the risk of hepatocellular cancer. There is currently no FDA-approved therapy for NASH and thus it becomes one of the major unmet medical needs of the present time.
Triangulum offers CRO services with extensive expertise in the following mouse models of NASH to our clients:
Normal mice fed with diet enriched in fat (40% kcal), fructose (22% by wt), and cholesterol (2% by wt). This model develops clinically relevant features of NASH over a prolonged period of time.
ob/ob mice fed with high fat diet Model
These mice are severely obese due to leptin deficiency and predisposed to develop steatohepatitis. ob/ob mice fed with diet enriched in fat (40% kcal), fructose (22% by wt), and cholesterol (2% by wt) develop clinically relevant features of NASH in a shorter duration.
Normal mice fed with MCD diet Model
MCD diet fed model shows the features of NASH-related inflammation and fibrosis that have been implicated in human NASH progression.
db/db mice fed with MCD diet Model
These mice are obese with insulin resistance, severe type 2 diabetes, and fatty livers due to a functional defect in their leptin receptor. MCD diet in this model exhibit the features of NASH-related inflammation and fibrosis that have been implicated in human NASH progression
Normal mice are fed with diet enriched in fat and diabetes is induced by streptozotocin administration. This model develops clinically relevant features of NASH where diabetes exacerbates the NASH phenotype.
Triangulum offers CRO services with extensive expertise in conducting preclinical efficacy, proof-of-concept and mechanism of action studies in various animal models of type 2 diabetes. Our scientists have outstanding track record of working with ob/ob, db/db, DIO-Streptozotocin, DIO mice as well as Zucker Diabetic Fatty (ZDF) rats and DIO-Streptozotocin rats. Our team has the skills and experience needed to evaluate your preclinical drug candidates such as small molecules, biologics and RNA therapeutics in acute and chronic efficacy studies. We provide hyperinsulinemic-euglycemic clamp studies, OGTT, IPGTT, ITT and histopathology services. Our scientists provide professional interpretation of the preclinical efficacy data to accelerate your drug development.
Drug Metabolism and Pharmaco-Kinetic (DMPK) studies are integral to understand the life and/or stability of the drug inside the organism and thus aid in determination of the required optimal dosage of the drug. While various factors such as Absorption, Distribution, Metabolism and Excretion could have mono- or multi-variate influence on the bioavailability of the drug once administered, a proper understanding of these processes is often necessary for drug development in pre-clinical stages and could provide valuable information for dose selection in First in Human (FIH) clinical trials. Further, knowledge gained from these studies is critical for repeated compound administration.
Our research team has extensive experience in rodent disease models, a variety of routes for investigative drug administration (IP, IV, IM, SC, PO) and extraction of various tissues to determine the bioavailability of the drug in target organs.
Our DMPK analysis team has significant experience in the analytical methods of drug development including but not limited to:
Our team can also assist with data analysis utilizing either non-compartmental or compartmental (single and/or multi-compartmental) modelling approaches and statistical analysis using SAS software.
In addition, we perform PD studies on the following NASH/NAFLD Models, Metabolic Disease Models and Muscle Disease Models.
Genetic Disorder Animal Models Services
Triangulum Biopharma has not received any reviews.
Triangulum Biopharma has not received any endorsements.